CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2013-06-10): FDA wants more safety data on hepatitis B vaccine


FDA wants more safety data on hepatitis B vaccine

Last Updated: 2013-06-10 12:40:22 -0400 (Reuters Health)

(Reuters) - Dynavax Technologies Corp said the U.S. Food and Drug Administration asked for additional safety data on its experimental hepatitis B vaccine, Heplisav.

The company said it will meet with the FDA shortly to discuss the protocol for collecting additional safety data, which it expects to include in the current approval application.

Heplisav was denied approval by the FDA in February, saying the safety data provided by the company was insufficient to support an approval.

The FDA said Dynavax's safety database needed additional subjects, the company said on Monday.

The company said it was also working on the questions raised by the FDA regarding the manufacturing and testing of Heplisav.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.